Introduction
Hemojuvelin (HJV) is a member of the repulsive guidance molecule (RGM) family, a family of glycosylphosphatidylinositol (GPI)-anchored neuronal and muscle membrane glycoproteins.
HJV (also called RGM-c) is mainly expressed in skeletal muscle, heart and liver, and plays a major role in regulating hepcidin expression, the negative regulator of intestinal iron absorption and macrophage heme iron recycling. Patients with HJV mutations develop early onset severe iron overload called juvenile haemochromatosis due to a complete lack of hepcidin expression (1) . HJV can be expressed both as a membrane-bound (mHJV) and as a soluble (sHJV) form that have opposite effects on hepcidin gene expression. Cell-associated HJV acts as a coreceptor of Bone Morphogenic Proteins (BMPs) to enhance hepcidin expression through the Smad pathway (2, 3) . On the reverse, sHJV, by binding BMP, acts as a competitive antagonist of mHJV, leading to decreased hepcidin expression (2) (3) (4) . Thus, chronic sHJV injection in mice causes iron overload (5) .
Several isoforms of HJV protein are generated by multiple proteolytic cleavages ( Figure 1 ).
Membrane-bound HJV protein can be represented by both single-and two-chain species. The two-chain species is produced from the single chain by an intra-molecular cleavage and the two chains can remain bound to the plasma membrane through the formation of disulphide bridge (6, 7) . Soluble hemojuvelin can be produced by a cleavage at the C-terminus of the protein occurring in the endoplasmic reticulum, mediated by a furin-like protease (8, 9) . This cleavage leads to the release of two soluble components (42 and 33 kDa) into extracellular fluids or into blood. These two fragments are probably produced from single-and two-chain species of HJV as suggested by the authors. Nevertheless, the fact that the 42 and 33 kDa fragments originating from a furin cleavage are released into the blood stream has not been confirmed.
The furin-mediated sHJV release can be enhanced by hypoxia and iron deficiency to reduce rapidly the amount of mHJV and to inhibit hepcidin production. Recently, it has been demonstrated that mHJV, the GPI anchored form, is cleaved by Matriptase 2, a transmembrane serine protease encoded by the TMPRSS6 gene, mostly expressed in the liver. Co-transfection experiments with vectors expressing HJV and Matriptase 2 have shown that this serine protease can cleave the mHJV to generate several smaller fragments (25-35 kDa) (10) but these fragments have not yet been identified in serum samples. The physiological role of these soluble HJV fragments and their presence in human serum remain to be investigated. However, mutational inactivation of matriptase 2 causes iron refractory iron-deficient anaemia (IRIDA) in mice (11) and humans (10, (12) (13) (14) , by inappropriately high levels of hepcidin expression. In summary, circulating hemojuvelin is represented by several soluble forms that can be produced by the action of at least two proteolytic enzymes, furin or matriptase 2.
The quantification of HJV in human blood may provide further insights into the pathogenesis of iron homeostasis disorders. Measurement of sHJV in biological fluids can improve our understanding of iron diseases and be a useful tool for their diagnosis and for the clinical management. This study describes a specific competitive immunoassay for sHJV quantification in human sera.
Design and Methods

Anti-HJV antibody and recombinant human RGM-c (rhRGM-c)
The HJV antibody was generated against a recombinant HJV protein encompassing amino acids 226 to 402 as previously described (15) . The HJV antibody was purified and conjugated to horseradish peroxidase (HRP) following the manufactured recommendation (Interchim, Montluçon, France).
The recombinant human RGM-c is produced by R&D system (Wiesbaden, Germany) as a fusion protein consisting in the human CD33 fused to the C-terminal polyhistidine-tagged 
Serum and tissue collection
The study population comprised 48 healthy individuals, 4 patients with iron refractory iron deficiency anaemia and TMPRSS6 mutations (IRIDA), and 36 patients with anaemia of chronic disease (ACD). The patients with ACD were selected in Intensive Care Unit of Bichat hospital, on the basis of CRP> 50 mg/L, Hb <10 g/dL and absence of known iron disorder,. Each patient included in this study provided signed informed consent. The experimental protocol was performed according to the French legislation on Ethics and Human Research. Serum samples were immediately frozen and stored at -80°C. Serum from a patient with the homozygous D149fsX245 HJV mutation was a kind gift from Laura Silvestri and Clara Camaschella (Milano, Italy). Normal muscle sample was used as control for Western blotting studies.
Serum hepcidin assay
Briefly, hepcidin concentrations were measured in duplicate using a competitive ELISA (Intrinsic LifeSciences, La Jolla, CA). HPLC-purified, synthetic, bioactive hepcidin (Bachem Biosciences Inc, King of Prussia, PA) was used as reference material for construction of duplicate 12 point standard curves, used to convert sample absorbance readings to hepcidin concentrations (16) .
Immunoprecipitation and Western blot
For immunoprecipitation, 500 !g of serum proteins were incubated overnight at 4°C with 4 !L of anti-HJV antibody in 200 !L of PBS. Then, a 20 !L aliquot of protein G PLUS-agarose was added for 2 h at 4°C. The mixture was centrifuged and the pellet was washed twice in PBS.
Prior to electrophoresis, sera were treated when indicated using the Aurum serum protein kit 
Statistical analysis
Statistical significance was calculated using the non-parametric Mann-Withney test and correlations were analyzed using the Spearman's rank correlation test; p <0.05 was considered as significant. GraphPad Prism software (GraphPad Software, San Diego, CA) was used for statistical evaluation.
Results
Identification of the electrophoretic pattern of serum HJV
Western blot analysis showed that the recombinant HJV protein (rhRGM-c) was detected by the polyclonal antibody against HJV (Figure 2A ). Several bands were observed; from the indications given by the manufacturer, it can be inferred that these correspond to the full-length mHJV (from Gln36 to Asp400, MW 50-55 kDa) and to the C-terminal fragment (Pro173 to Asp400, MW 37 kDa), generated by intra-molecular cleavage at the conserved consensus Gly-Asp-Pro-His site ( Figure 1) (7) . The N-terminal fragment (Gln36 to Asp172, 20 kDa) is not recognized by the antibody since it was generated against a recombinant protein from AA 226 to 402. The presence of two additional bands for each fragment probably reflects differences in glycosylation pattern as reported by Maxson et al (17) . In muscle extracts, only two bands are seen which may correspond to full-length mHJV and to the C-terminal glycosylated fragment as previously described (6) . In serum samples, albumin (~60-70% of the total serum protein), and immunoglobulin G (IgGs) (~10-20% of total serum protein) are major components that can mask the presence of many underlying smaller and similar size proteins, limiting the amount of serum that can be resolved on Western blotting. Therefore, we used the Aurum serum protein mini kit specifically designed to eliminate albumin and IgGs. As shown in Figure 2B (line 1), a significant amount of these proteins was eliminated and the identification of serum HJV bands was greatly improved as compared to total serum (line 2). In these conditions, two specific bands were identified, of 42 kDa and 33 kDa, which could correspond to the previously described fragments produced by furin cleavage (Figure 1 ). These bands were absent in the serum of a patient with the homozygous D149fsX245 mutation in Hjv gene ( Figure 2B, line 4) (18). This one bp deletion in exon 3 creates a frame shift and premature STOP codon, 96 amino acids downstream of Asp149. Even if this shorter form of HJV is produced, it will not be recognized by the polyclonal antibody generated against a recombinant protein from AA 226 to 402. Western blot analysis showed an additional band around 40 kDa that appears to be either related to different glycosylation pattern or to a non specific signal ( Figure 2B ). However, its absence in the serum from the patient with HJV mutation suggests that this band is specifically recognized by the antibody. Finally, in order to confirm the specific binding of our antibody to HJV we performed a Western blotting using serum proteins immunoprecipitated with HJV antibody ( Figure 2C ). Serum immunoprecipitation permits to obtain an HJV-depleted supernatant ( Figure 2C ,a) and high amount of HJV in the corresponding precipitate ( Figure   2C ,b). When we omit the HJV antibody in the Western blot ( Figure 2C,c) , the remaining bands corresponded to the immunoglobulins of HJV antibody used for the immunoprecipitation.
Besides, in order to ascertain the antibody specificity, we used HJV antibody conjugated to HRP which permits to avoid the addition of secondary antibody and to reveal the specific bands corresponding to sHJV fragments ( Figure 2C,d) . We can conclude that IgG bands are revealed by the secondary antibody while the HJV antibody binds solely to HJV.
Development and characterization of an ELISA assay for serum HJV measurement.
The recombinant peptide (rhRGM-c protein) and the polyclonal antibody against HJV were used for the development of an immunological assay aiming at the quantification of circulating HJV in human serum. In a preliminary experiment, we determined the optimal dilution of antibody and the optimal concentration of antigen according to Crowther (19) . A curve was obtained by adding serial dilutions of the antibody in wells coated with 200 ng recombinant HJV. Figure 3A showed that the optimal signal and lowest background for the ELISA were obtained with the dilution 1:25,000 for the antibody.
A typical calibration curve obtained with the rhRGM-c protein as calibrator is shown in Figure 3B and 3C (black triangles). In order to test the matrix effect, a calibration was repeated using a sHJV-depleted serum ( Figure 3B ) or HJV deficiency serum ( Figure 3C ). The curve of the HJVdepleted serum was shifted compared to the curve obtained with BSA because of the presence of endogenous sHjv as observed in Figure 2C . Similar profiles were obtained in PBS and in HJV deficiency serum ( Figure 3C ). Several serum sample volumes (5-30 !L) were then tested and the adequate volume was estimated at 10 !L ( Figure 3D) . A low (10 ng i.e. 1 mg/L ) and a high concentration (100 ng i.e. 10 mg/L) of calibrator were used for statistical analysis of the reproducibility, linearity and recovery of the sHJV ELISA assay. The intra-assay coefficients of variance (CVs) were 9.1 and 2.6 for low and high concentrations respectively as evaluated by assaying five replicates of each sample in a single assay ( Table 1 ).
The inter-assay CVs were 4.1-5.8% as evaluated by four subsequent measurements of the test samples. Intra-and inter-assay CVs for serum samples were 15% and 9.5% respectively ( Table   1 ).
Soluble HJV concentration in healthy volunteers
Circulating HJV concentration was determined in serum of 48 healthy volunteers (control group C1; 18 men, 30 women). Haematological parameters and iron indices of these healthy individuals are shown in Table 2 . The 5% to 95% range of hemojuvelin concentrations varied from 0.88 to 1.14 mg/L (mean: 1.01 ± 0.06 mg/L; n=48) with no significant difference between men (0.92 to 1.30 mg/L) and women (0.78 to 1.13 mg/L).
Soluble HJV concentration in IRIDA and ACD
Serum samples from patients with iron disorders (Table 2) were tested and compared with control group. We found a significant decrease in serum HJV concentration (mean=0.47 mg/L; n=4) in the IRIDA patients ( Figure 4A ) when compared to the control group of adult individuals (group C1; p=0.028) or to an age-matched control group (group C2; p=0.006). In the group of patients with anaemia of chronic disease (ACD), mean sHJV concentration was significantly higher (2.30 mg/L ± 0.27 mg/L, p<0.0001; n=37) than in the control group. The 5% to 95% range of hemojuvelin concentrations in ACD group varied from 1.73 to 2.85 mg/L with a maximum of 7.33 mg/L. Western blot analysis of two IRIDA serum confirmed the reduced level of both the 42 kDa and the 33 kDa HJV bands as compared to one control serum ( Figure 4B) whereas the intensity of these two bands was increased in three sera from ACD patients as compared to three control sera ( Figure 4B ). These results are consistent with those of ELISA. was not correlated with hepcidin concentrations from 28 patients belonging to the ACD group in which serum hepcidin values were available (r=0.22; p=0.26) (data not shown). Finally, ELISA test has been done to measure HJV in serum from the patient with HJV mutation that has been used for western blotting in Figure 2B . The obtained result is 0.3 mg/L which is decreased considering the normal range (0.88 to 1.14 mg/L).
Discussion
The present study describes the first immunological assay for hemojuvelin quantification in human serum, based on the use of a recombinant rhRGM-c peptide and a polyclonal anti-HJV antibody. The Western blot analysis of serum HJV performed to confirm the specificity of the antibody revealed two major components corresponding to the 33 kDa C-terminal fragment and the 42 kDa soluble forms of HJV. Indeed, several isoforms of circulating HJV may exist. The shorter fragments resulting from Matriptase 2 cleavage may be either contained into the 33 kDa band or have too limited abundance to be detected by Western blot. In order to quantify all these circulating HJV forms, we chose to set up a competitive ELISA technique using an antibody against HJV able to recognize rhRGM-c peptide and the native serum HJV forms.
Thereby, we achieved intra and inter CVs ranging from 2.6 to 15%, attesting the reproducibility of the method.
As a preliminary step in evaluating the usefulness of this assay in clinical situations, we assessed the concentrations of circulating HJV in a control group and in group of patients with iron disorders (IRIDA with a mutation in the TMPRSS6 gene or anaemia of chronic diseases). In healthy controls, serum HJV values ranged from 0.88 to 1.14 mg/L with no difference between men and women.
In IRIDA patients with TMPRSS6 mutations that induce failure in the matriptase 2 activity (13), we found significantly lower serum HJV levels than in healthy patients. In these patients, hypochromic microcytic anaemia and high hepcidin level were reported (13, 14) , however HJV concentration was not assessed previously. Our findings suggest that matriptase 2 mutation may induce a decrease of circulating HJV forms but the link between this mutation and serum HJV production remains to be investigated. Moreover, the potential physiological role of sHJV fragments produced by the matriptase 2 is not yet characterized.
In a group of patients with anaemia of chronic disease, we found that serum HJV concentrations were significantly higher than in the controls. The soluble form of HJV is thought to be a negative regulator of hepcidin expression but its role in the regulation of hepcidin upon inflammation stimulus remains unclear. HJV production plays a key role in dietary iron sensing (20) . Besides, several studies have shown that HJV expression is repressed in mice at a transcriptional level by a pro-inflammatory stimulus (21, 22) . Moreover, Babitt et al (5) Altogether, these preliminary observations suggest that this ELISA test could be useful in improving our understanding of the regulation of serum HJV production and its pathogenic role in various iron disorders. They also indicate that circulating HJV could be a potential new treatment for anaemia associated with hepcidin excess as in IRIDA patients with mutation in TMPRSS6 gene or in inflammatory anemia.
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